Journal
BEHAVIOURAL PHARMACOLOGY
Volume 17, Issue 5-6, Pages 379-382Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00008877-200609000-00003
Keywords
genetic mouse models; MPTP; Parkinson's disease; primate models; progression
Ask authors/readers for more resources
Parkinson's disease is a progressive neurodegenerative disorder. At present, only symptomatic treatments are of proven efficacy, whereas strategies that slow or stop the neurodegenerative process are currently not available. The selection of interesting drug candidates or surgical strategies should be based on the soundest clinically driven preclinical validation. My goal here is not to discuss the relative merits of the available models, but to simply raise the issue of the experimental design that has led to the demonstration of efficacy of given compounds in these models. As some compounds previously shown to be active in classic experimental designs fail when tested in clinically relevant experimental designs, I emphasize the need for progressive screening methods and for the use of different animal species before entering into the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available